Bildkälla: Stockfoto

Amniotics Q4 2022: Our Comments - Redeye

Redeye comments on the events of the fourth quarter, including progress with the main candidate PulmoStem and the rights issue.

Redeye comments on the events of the fourth quarter, including progress with the main candidate PulmoStem and the rights issue.
Börsvärldens nyhetsbrev
ANNONSER